IN2014DN02060A - - Google Patents

Info

Publication number
IN2014DN02060A
IN2014DN02060A IN2060DEN2014A IN2014DN02060A IN 2014DN02060 A IN2014DN02060 A IN 2014DN02060A IN 2060DEN2014 A IN2060DEN2014 A IN 2060DEN2014A IN 2014DN02060 A IN2014DN02060 A IN 2014DN02060A
Authority
IN
India
Prior art keywords
patient
benzimidazol
methylpiperazin
quinolin
tautomer
Prior art date
Application number
Other languages
English (en)
Inventor
Suraj Prakash Anand
Catherine Wynnette Reddick
Michael Shi
Mary Ellen Steed
Eugene Youchin Tan
Yongyu Wang
Mario Reinhard Stegert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN02060A publication Critical patent/IN2014DN02060A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN2060DEN2014 2011-09-15 2012-09-07 IN2014DN02060A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535142P 2011-09-15 2011-09-15
PCT/US2012/054046 WO2013039764A1 (fr) 2011-09-15 2012-09-07 Utilisation de la 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one dans le traitement du cancer chez des patients atteints d'une insuffisance hépatique modérée

Publications (1)

Publication Number Publication Date
IN2014DN02060A true IN2014DN02060A (fr) 2015-05-15

Family

ID=46846036

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2060DEN2014 IN2014DN02060A (fr) 2011-09-15 2012-09-07

Country Status (12)

Country Link
US (1) US20140221389A1 (fr)
EP (1) EP2755655A1 (fr)
JP (1) JP2014526506A (fr)
KR (1) KR20140062485A (fr)
CN (1) CN103826634A (fr)
AU (1) AU2012308993A1 (fr)
BR (1) BR112014005653A2 (fr)
CA (1) CA2848210A1 (fr)
IN (1) IN2014DN02060A (fr)
MX (1) MX2014003182A (fr)
RU (1) RU2014114827A (fr)
WO (1) WO2013039764A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2764866A1 (fr) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibiteurs de l'enzyme activant nedd8
EP3093014A1 (fr) * 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel et son utilisation pour le traitement du cancer
CA3150729A1 (fr) * 2019-09-11 2021-03-18 Inspirna, Inc. Methodes de traitement du cancer
TWI888447B (zh) 2019-12-13 2025-07-01 美商因思博納公司 金屬鹽及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60115069T2 (de) 2000-09-11 2006-08-03 Chiron Corp., Emeryville Chinolinonderivate als tyrosin-kinase inhibitoren
EP1539754A4 (fr) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic Quinolinones de benzimidazole et leurs utilisations
CN100377709C (zh) * 2002-11-13 2008-04-02 希龙公司 受体酪氨酸激酶抑制剂的制药用途及相关检测方法
SG148864A1 (en) * 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
ATE439133T1 (de) * 2003-05-27 2009-08-15 Robert P Haegerkvist Verwendung von tyrosin-kinase-hemmern zur behandlung von diabetes
BRPI0611375A2 (pt) * 2005-05-23 2010-08-31 Novartis Ag formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
PE20091628A1 (es) 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
CN102781237A (zh) * 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物

Also Published As

Publication number Publication date
MX2014003182A (es) 2014-09-22
BR112014005653A2 (pt) 2017-03-28
JP2014526506A (ja) 2014-10-06
CA2848210A1 (fr) 2013-03-21
KR20140062485A (ko) 2014-05-23
CN103826634A (zh) 2014-05-28
WO2013039764A1 (fr) 2013-03-21
AU2012308993A1 (en) 2014-03-27
EP2755655A1 (fr) 2014-07-23
RU2014114827A (ru) 2015-10-20
US20140221389A1 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
UA114726C2 (uk) 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
UA118759C2 (uk) Сполуки 3,4-дигідроізохінолін-2(1н)-ілу
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
PH12015501965A1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
IN2014DN10670A (fr)
IN2014MN00988A (fr)
MX2014004122A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas.
IN2014MN01640A (fr)
IN2015MN00002A (fr)
NZ709153A (en) Pyrimidinone derivatives having human neutrophil elastase inhibitory activity
HK1212977A1 (zh) 苯達莫司汀衍生物及其使用方法
WO2014160281A3 (fr) Procédé pour améliorer l'administration de composés thérapeutiques à l'œil
PH12015501586A1 (en) 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201391171A1 (ru) Формы рифаксимина и их применение
IN2015DN01151A (fr)
MY196185A (en) Salts of a Pim Kinase Inhibitor
SG10201900541QA (en) Derivatives of xanthone compounds
MX357763B (es) Tratamiento para cancer pancreatico.
NZ700356A (en) Pyrazole compounds as sglt1 inhibitors
IN2014DN02060A (fr)
PH12014500577A1 (en) Sulfonic acid salts of heterocyclylamide-substituted imidazoles
PH12014501051A1 (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
MY180727A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzeimer?s disease